RxDoctor Payments Data

Lisa Wallace

Family · Florence, SCNPI 1235637182

Payments from drug & device makers

$7,305in general payments, 2019–2025

Across 438 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$792
  • Novo Nordisk$731
  • AstraZeneca$583
  • GSK$568
  • Pfizer$566
  • Boehringer Ingelheim$367
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,305 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$116,683
Medicare patients
428
Services billed
2,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$135,693
OzempicSemaglutide84$102,898
EliquisApixaban70$67,096
RybelsusSemaglutide40$55,194
TrulicityDulaglutide43$46,455
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$40,476
JanuviaSitagliptin Phosphate33$36,769
XareltoRivaroxaban18$28,054
MounjaroTirzepatide19$23,597
MyrbetriqMirabegron16$21,184
LinzessLinaclotide20$20,201
Janumet XrSitagliptin Phos/Metformin Hcl37$19,122
FarxigaDapagliflozin Propanediol16$18,027
Tresiba Flextouch U-200Insulin Degludec18$17,566
VraylarCariprazine Hcl12$17,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$731$158,091124 claims
Boehringer IngelheimJardiance$367$135,693101 claims
Lilly USA, LLCTrulicity, Mounjaro$223$70,05262 claims
PfizerEliquis$566$67,09670 claims
MerckJanuvia, Janumet Xr$146$55,89170 claims
GSKTrelegy Ellipta$568$40,47633 claims
AbbVieLinzess, Vraylar, Synthroid$792$39,32562 claims
Johnson & JohnsonXarelto$108$28,05418 claims
AstraZenecaFarxiga, Symbicort$583$23,80530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →